Resources
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 20 October 2023
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 16th meeting on 20 October 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 23 August 2023
This communique provides a summary of the advisory committee's meeting on 23 August 2023.
National Site of Recognition Steering Committee communique – 10 July 2023
Details of the fifth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 10 July 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 21 July 2023
This communique provides a summary of the advisory committee's meeting on 21 July 2023.
Chronic health plans – Easy Read
This fact sheet tells you about health care plans for chronic health problems. Chronic means something lasts a long time. Chronic health problems last a long time. You can download the fact sheet in PDF to read online or print.
Referral form for chronic disease allied health services under Medicare
GPs can use this referral form to refer a patient with a chronic medical condition and complex care needs for Medicare rebateable allied health services under the Chronic Disease Management (CDM) Medicare items.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 4 July 2023
This communique provides a summary of the advisory committee's meeting on 4 July 2023.
Newborn bloodspot screening – Public consultation infographic
This publication outlines the key findings from our public consultation on the expansion of newborn bloodspot screening programs.
Public consultation on the expansion of newborn bloodspot screening
This report gives an overview of the public consultation process that we undertook for the expansion of newborn bloodspot screening programs.
National Fetal Alcohol Spectrum Disorder (FASD) Strategic Action Plan 2018-2028 – Three-year implementation review
This report shares review findings of the National Fetal Alcohol Spectrum Disorder (FASD) Strategic Action Plan 2018-2028 implementation. The review’s aim is to inform the Australian Government if the plan is on-track to achieving its goals.
Key updates for Aboriginal and Torres Strait Islander communities – March 2023
This newsletter provides key health updates for Aboriginal and Torres Strait Islander households, communities and stakeholders.
Key updates for Aboriginal and Torres Strait Islander communities – April 2023
This newsletter provides key health updates for Aboriginal and Torres Strait Islander households, communities and stakeholders.
Life Saving Drugs Program – Sebelipase alfa (Kanuma®) outcome statement
Summary of the consideration of the application from Alexion Australia for the inclusion of sebelipase alfa (Kanuma®) on the LSDP for the treatment of infantile onset lysosomal acid lipase deficiency (LAL-D).
Life Saving Drugs Program – Fact sheet for treating physicians
This fact sheet gives answers to common questions about the role of treating physicians in prescribing Life Saving Drugs Program (LSDP) medicines.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 26 May 2023
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 15th meeting on 26 May 2023.
Life Saving Drugs Program – Fact sheet for patients
Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.
Life Saving Drugs Program – Change of treating physician form
Use this form to help transition a patient’s care to a new physician, where there are no other changes to their treatment or eligibility for the Life Saving Drugs Program (LSDP).
National Occupational Respiratory Disease Registry – Patient notification questions
This form collects information on individuals with a respiratory disease that was occupationally caused for entry into the National Occupational Respiratory Disease Registry (NORDR). Physicians can print this form and hand it to the patient or it can be filled in online by the patient.
Life Saving Drugs Program – Gaucher disease (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Initial application
Treating Physicians use this application form to apply for a patient to access LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) for the first time, or after a break.
Life Saving Drugs Program – Gaucher disease (type 1) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.
Life Saving Drugs Program – Gaucher disease (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.
Life Saving Drugs Program – Spreadsheet for infantile-onset lysosomal acid-lipase deficiency disease (LAL-D)
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D).
Date last updated: